Skip to main content

Table 1 Baseline characteristics

From: Prognostic nomogram for patients with unresectable pancreatic cancer treated with gemcitabine plus nab–paclitaxel or FOLFIRINOX: A post–hoc analysis of a multicenter retrospective study in Japan (NAPOLEON study)

  n=318
Age (years), n (%)  
<60 93 (29)
60 – 70 137 (43)
>70 88 (28)
Sex (M/F), n (%) 196/122 (62/38)
ECOG PS, n (%)  
0 204 (64)
1 96 (30)
2 or more 17 (5)
Body mass index (kg/m2), n (%)  
<22 198 (62)
≥22 120 (38)
Tumor resection, n (%) 44 (14)
Pancreatic tumor location, n (%)  
Head 165 (52)
Body 94 (30)
Tail 59 (19)
Tumor size (mm), n (%) 32 (1 – 98)
<20 41 (13)
20 – 40 181 (57)
>40 96 (30)
Histology, n (%)  
Adenocarcinoma 271 (85)
Others 47 (15)
Unknown 37 (12)
Site of metastatic disease, n (%)  
Liver 154 (48)
Peritoneum 62 (19)
Lung 39 (12)
Number of metastatic sites, n (%)  
≥2 97 (31)
Ascites, n (%) 62 (19)
Albumin (g/dL), n (%)  
>4 32 (10)
3 – 4 181 (57)
<3 105 (33)
LDH (U/L), n (%)  
<240 269 (85)
240 – 360 105 (33)
>360 8 (3)
CRP (mg/dL), n (%)  
<0.3 158 (50)
0.3 – 3.0 117 (37)
>3.0 43 (14)
CA19–9 (U/mL), n (%)  
<37 76 (24)
37 – 370 72 (23)
>370 170 (53)
AJCC TNM stage, n (%)  
III 63 (20)
IV 255 (80)
First line regimen, n (%)  
GnP 200 (63)
FFX 118 (37)
  1. Abbreviations: ECOG PS Eastern Cooperative Oncology Group performance status, LDH lactate dehydrogenase, CRP C–reactive protein, CA19–9 carbohydrate antigen 19–9, AJCC American Joint Committee on Cancer, GnP gemcitabine plus nab–paclitaxel, FFX FOLFIRINOX